TLIS vs. AXDX, HLTH, TBIO, PRPO, OMIC, RPID, LUCD, BNGO, CCLD, and QTI
Should you be buying Talis Biomedical stock or one of its competitors? The main competitors of Talis Biomedical include Accelerate Diagnostics (AXDX), Cue Health (HLTH), Telesis Bio (TBIO), Precipio (PRPO), Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Lucid Diagnostics (LUCD), Bionano Genomics (BNGO), CareCloud (CCLD), and QT Imaging (QTI). These companies are all part of the "medical" sector.
Accelerate Diagnostics (NASDAQ:AXDX) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Accelerate Diagnostics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
Accelerate Diagnostics has higher revenue and earnings than Talis Biomedical. Talis Biomedical is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics currently has a consensus target price of $1.00, indicating a potential upside of 12.32%. Talis Biomedical has a consensus target price of $5.00, indicating a potential downside of 44.14%. Given Talis Biomedical's stronger consensus rating and higher probable upside, equities analysts plainly believe Accelerate Diagnostics is more favorable than Talis Biomedical.
In the previous week, Accelerate Diagnostics had 5 more articles in the media than Talis Biomedical. MarketBeat recorded 8 mentions for Accelerate Diagnostics and 3 mentions for Talis Biomedical. Accelerate Diagnostics' average media sentiment score of 0.23 beat Talis Biomedical's score of 0.06 indicating that Talis Biomedical is being referred to more favorably in the news media.
Accelerate Diagnostics received 345 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 63.33% of users gave Accelerate Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.
17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 46.0% of Talis Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Accelerate Diagnostics has a net margin of -452.28% compared to Accelerate Diagnostics' net margin of -5,784.73%. Talis Biomedical's return on equity of 0.00% beat Accelerate Diagnostics' return on equity.
Summary
Accelerate Diagnostics beats Talis Biomedical on 12 of the 18 factors compared between the two stocks.
Get Talis Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talis Biomedical Competitors List
Related Companies and Tools
